Imuran Mitis (Azathioprine)

Azathioprine is a prodrug that is converted inside cells to 6‑mercaptopurine. This metabolite blocks the synthesis of purine nucleotides, which are essential for DNA and RNA production. By limiting nucleotide availability, the drug reduces the proliferation of T and B lymphocytes, thereby dampening the immune response.

The dose of Imuran Mitis is individualized by the prescribing clinician. Factors such as the specific disease being treated, patient weight, renal and hepatic function, and the activity of the enzyme thiopurine methyltransferase (TPMT) are considered. Dose adjustments are made based on laboratory monitoring and clinical response.

Data on azathioprine use in pregnancy and lactation are limited. The drug crosses the placenta and is excreted in breast milk, so it is generally avoided unless the therapeutic benefit outweighs potential risks. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives and risk assessment with their healthcare provider.

To request Imuran Mitis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any necessary import documentation.

Both azathioprine (Imuran Mitis) and mycophenolate mofetil are immunosuppressants used in transplant and autoimmune settings, but they act via different pathways. Azathioprine interferes with purine synthesis through 6‑mercaptopurine, while mycophenolate inhibits inosine monophosphate dehydrogenase. Their side‑effect profiles differ; azathioprine is more associated with bone‑marrow suppression, whereas mycophenolate often causes gastrointestinal upset.

Imuran Mitis tablets should be stored at ambient temperature, below 25 °C. Keep them in the original packaging to protect from moisture and light. Do not store in areas of high humidity or near heat sources, and keep out of reach of children.

Imuran Mitis is taken orally as a tablet. The tablet should be swallowed whole with a glass of water, preferably with food or a light snack to lessen gastrointestinal irritation. The exact dosing schedule is determined by the prescribing clinician.

The most serious adverse effects of azathioprine include severe bone‑marrow suppression leading to pancytopenia, hepatotoxicity that can progress to hepatitis or liver failure, heightened susceptibility to serious infections, and a rare increased risk of certain malignancies such as lymphoma or skin cancer. Regular laboratory monitoring is essential to detect these complications early.

Imuran Mitis should be avoided in individuals with known hypersensitivity to azathioprine or its metabolites, those with severe hepatic impairment, active uncontrolled infections, or significant bone‑marrow deficiency. Caution is also advised for patients with TPMT deficiency, as they are at higher risk for toxicity. Pregnant or breastfeeding women should only use it when clearly indicated by a physician.